269 related articles for article (PubMed ID: 23269489)
1. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.
Chitalia VC; Shivanna S; Martorell J; Balcells M; Bosch I; Kolandaivelu K; Edelman ER
Circulation; 2013 Jan; 127(3):365-76. PubMed ID: 23269489
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD.
Walker JA; Richards S; Whelan SA; Yoo SB; Russell TL; Arinze N; Lotfollahzadeh S; Napoleon MA; Belghasem M; Lee N; Dember LM; Ravid K; Chitalia VC
J Am Soc Nephrol; 2021 Nov; 32(11):2834-2850. PubMed ID: 34716244
[TBL] [Abstract][Full Text] [Related]
3. Uremic serum and ubiquitylation of tissue factor.
Mackman N
Circulation; 2013 Jan; 127(3):320-1. PubMed ID: 23269490
[No Abstract] [Full Text] [Related]
4. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.
Gondouin B; Cerini C; Dou L; Sallée M; Duval-Sabatier A; Pletinck A; Calaf R; Lacroix R; Jourde-Chiche N; Poitevin S; Arnaud L; Vanholder R; Brunet P; Dignat-George F; Burtey S
Kidney Int; 2013 Oct; 84(4):733-44. PubMed ID: 23636172
[TBL] [Abstract][Full Text] [Related]
5. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia.
Shivanna S; Kolandaivelu K; Shashar M; Belghasim M; Al-Rabadi L; Balcells M; Zhang A; Weinberg J; Francis J; Pollastri MP; Edelman ER; Sherr DH; Chitalia VC
J Am Soc Nephrol; 2016 Jan; 27(1):189-201. PubMed ID: 26019318
[TBL] [Abstract][Full Text] [Related]
6. Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.
Kolachalama VB; Shashar M; Alousi F; Shivanna S; Rijal K; Belghasem ME; Walker J; Matsuura S; Chang GH; Gibson CM; Dember LM; Francis JM; Ravid K; Chitalia VC
J Am Soc Nephrol; 2018 Mar; 29(3):1063-1072. PubMed ID: 29343519
[TBL] [Abstract][Full Text] [Related]
7. Indolic uremic solutes enhance procoagulant activity of red blood cells through phosphatidylserine exposure and microparticle release.
Gao C; Ji S; Dong W; Qi Y; Song W; Cui D; Shi J
Toxins (Basel); 2015 Oct; 7(11):4390-403. PubMed ID: 26516916
[TBL] [Abstract][Full Text] [Related]
8. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
10. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair.
Dou L; Bertrand E; Cerini C; Faure V; Sampol J; Vanholder R; Berland Y; Brunet P
Kidney Int; 2004 Feb; 65(2):442-51. PubMed ID: 14717914
[TBL] [Abstract][Full Text] [Related]
11. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk.
Shashar M; Belghasem ME; Matsuura S; Walker J; Richards S; Alousi F; Rijal K; Kolachalama VB; Balcells M; Odagi M; Nagasawa K; Henderson JM; Gautam A; Rushmore R; Francis J; Kirchhofer D; Kolandaivelu K; Sherr DH; Edelman ER; Ravid K; Chitalia VC
Sci Transl Med; 2017 Nov; 9(417):. PubMed ID: 29167396
[TBL] [Abstract][Full Text] [Related]
12. Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease.
Jhawar S; Singh P; Torres D; Ramirez-Valle F; Kassem H; Banerjee T; Dolgalev I; Heguy A; Zavadil J; Lowenstein J
PLoS One; 2015; 10(3):e0118703. PubMed ID: 25811877
[TBL] [Abstract][Full Text] [Related]
13. Does uremia cause vascular dysfunction?
Brunet P; Gondouin B; Duval-Sabatier A; Dou L; Cerini C; Dignat-George F; Jourde-Chiche N; Argiles A; Burtey S
Kidney Blood Press Res; 2011; 34(4):284-90. PubMed ID: 21691132
[TBL] [Abstract][Full Text] [Related]
14. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
[TBL] [Abstract][Full Text] [Related]
15. N-Acetylcysteine and Sulodexide Reduce the Prothrombotic Effect of Uremic Serum on the Venous Endothelial Cells.
Sosinska-Zawierucha P; Mackowiak B; Breborowicz A
Kidney Blood Press Res; 2019; 44(2):277-285. PubMed ID: 30959503
[TBL] [Abstract][Full Text] [Related]
16. Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients.
Paats J; Adoberg A; Arund J; Dhondt A; Fernström A; Fridolin I; Glorieux G; Leis L; Luman M; Gonzalez-Parra E; Perez-Gomez VM; Pilt K; Sanchez-Ospina D; Segelmark M; Uhlin F; Arduan Ortiz A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102247
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells.
Addi T; Poitevin S; McKay N; El Mecherfi KE; Kheroua O; Jourde-Chiche N; de Macedo A; Gondouin B; Cerini C; Brunet P; Dignat-George F; Burtey S; Dou L
Arch Toxicol; 2019 Jan; 93(1):121-136. PubMed ID: 30324315
[TBL] [Abstract][Full Text] [Related]
18. Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis.
Belmokhtar K; Robert T; Ortillon J; Braconnier A; Vuiblet V; Boulagnon-Rombi C; Diebold MD; Pietrement C; Schmidt AM; Rieu P; Touré F
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):800-9. PubMed ID: 26988587
[TBL] [Abstract][Full Text] [Related]
19. Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay.
Calaf R; Cerini C; Génovésio C; Verhaeghe P; Jourde-Chiche N; Bergé-Lefranc D; Gondouin B; Dou L; Morange S; Argilés A; Rathelot P; Dignat-George F; Brunet P; Charpiot P
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2281-6. PubMed ID: 21727042
[TBL] [Abstract][Full Text] [Related]
20. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
